HLS Therapeutics Inc. (OTCMKTS:HLTRF) Shares Shorted: Short Interest Up 1,746.0% in October

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the recipient of a large increase in short interest in October. As of October 30th, there was short interest totaling 1,846 shares, an increase of 1,746.0% from the October 15th total of 100 shares. Based on an average daily volume of 4,910 shares, the days-to-cover ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial upgraded shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy”.

HLS Therapeutics Price Performance

Shares of HLS Therapeutics stock remained flat at $3.20 on Tuesday. The firm’s 50-day moving average price is $2.86 and its 200 day moving average price is $3.09. HLS Therapeutics has a fifty-two week low of $2.64 and a fifty-two week high of $3.70.

About HLS Therapeutics

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, licensing, developing and commercializing prescription medicines. Rather than primarily discovering new drugs, the company generally builds value by obtaining rights to established or differentiated pharmaceutical products and supporting their regulatory approval, market access and commercial distribution. The company’s activities have centered on specialty-care and hospital-related therapies, including products for central nervous system and cardiovascular conditions.